At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 306 enrolled
Drug / intervention
Botulinum Toxins, Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)
In Brief
A Phase 3 clinical trial evaluating Botulinum Toxins, Type A and Placebos for Glabellar Frown Lines. Completed, enrolled 306 participants across 14 sites in 2 countries.
Detailed Summary
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJan 2017
Primary CompletionNov 2017
TodayJul 2026
First PostedJan 9, 2017
Enrollment StartDec 5, 2016
Primary CompletionNov 3, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.5 years ago
Interventions
Botulinum Toxins, Type Abiological
Intramuscular injection
Placebosbiological
Intramuscular injection